Scott Patterson to Present at GTC’s 7th Oncology Biomarkers Mtg. on Mar 19-21, 2014 in San Diego

San Diego, CA, November 24, 2013 --(PR.com)-- Scott Patterson, Executive Director of Medical Sciences at Amgen will give a featured presentation on “Continued Exploration of Tumor Molecular Characteristics Further Improves Patient Outcomes” at the 7th Oncology Biomarkers Conference (March 19-21, 2014 in San Diego, CA).

In his presentation Dr. Patterson will describe how the development of targeted therapeutics for global populations requires identification of that segment of the patient population that displays the greatest benefit:risk profile, enabling demonstration of the value of the therapeutic to patients and associated stakeholders. When expression level variation or mutation status of the therapeutic target does not confer predictive value, examination of downstream pathway elements may prove valuable. Such is the case for therapeutic antibodies directed against the EGF receptor. Since confirmation of the negative predictive value of the most common somatic mutations in KRAS exon 2, studies have been undertaken to determine if additional biomarkers can be employed to further define the patient population most likely to benefit from this therapeutic approach. Dr. Patterson will describe the strategy of hypothesis generation and testing and the methods employed over the past seven years.

The 7th Oncology Biomarkers Conference brings together experts from industry and academia to discuss the latest developments in the biomarkers and diagnostics arena specifically to the field of oncology. This conference is part of the larger Biomarker Summit 2014 which includes the following co-located conferences:

1) 3rd Neurological Biomarkers
2) 3rd Inflammatory & Immunological Biomarkers

For more information, please visit www.gtcbio.com/biomarkers/oncology